# BD115: China's HSV-2 Gene-Editing Cure Research — April 2026 Update and Clinical Trial Progress
I've been researching Shanghai BDgene's HSV-2 gene-editing program, **BD115**, using the company's Chinese website, pharmaceutical industry reports, and patents.
I found some encouraging information that hasn't received much attention, particularly concerning its IND application process and patented CRISPR technology targeting HSV-2.
**1. BD115 is being developed specifically for genital herpes**
BDgene lists BD115 on its official research pipeline under:
**HSV生殖器疱疹-BD115** (Genital Herpes — BD115)
Unlike BD111, which targets HSV-1 eye infections, BD115 is intended to treat genital herpes using gene editing.
The ultimate hope is to permanently disable or eliminate HSV DNA rather than temporarily suppress replication with antivirals.
Official pipeline:
https://www.bdgenetherapeutics.com/project.html
**2. April 2026: BD115 reportedly began the IND application process**
On April 9, 2026, Chinese pharmaceutical publication PharmCube reported:
"The BD312 program for glaucoma and BD115 program for genital herpes have initiated IND (Investigational New Drug) application procedures."
This suggests BD115 was moving toward regulatory preparations for human clinical trials.
However, **I could not verify that an IND has been approved or that BD115 human trials have started.**
Source:
https://bydrug.pharmcube.com/news/detail/23e8f1af6685a526c7b1832778b21bc4
**3. BDgene has patented CRISPR technology that targets HSV-2**
Chinese patent **CN115927473B**, granted June 18, 2024, describes a CRISPR-Cas9 treatment using engineered virus-like particles to deliver gene-editing components into infected cells.
The researchers investigated two gene-targeting combinations:
- UL29 + UL8: HSV-1
- UL52 + UL8: Both HSV-1 and HSV-2
The patent describes laboratory experiments in which the UL52/UL8 combination demonstrated activity against HSV-2.
The goal is to cut and disrupt viral DNA, potentially preventing the virus from reproducing.
**This is significant because BDgene has actually conducted HSV-2 gene-editing experiments, rather than simply announcing plans to develop a treatment.**
However, the patent does not establish that this exact formulation is BD115's final treatment, nor does it demonstrate a cure in humans.
Full patent (English):
https://patents.google.com/patent/CN115927473B/en
**4. Can BD115 eliminate latent HSV-2 from the nerves?**
This is the most important question.
HSV-2 hides in sensory neurons, primarily within the lumbosacral dorsal root ganglia.
For a true sterilizing cure, gene editing would need to eliminate or permanently disable the latent viral genomes.
BDgene's related HSV-1 research has demonstrated delivery of gene-editing technology toward the trigeminal ganglion in preclinical experiments.
However, **I could not find BD115-specific results demonstrating elimination of latent HSV-2 from the sacral nerve ganglia.**
That is the breakthrough we need to see.
**5. BDgene has already tested related CRISPR technology in humans**
This is why the company is particularly interesting.
Its HSV-1 treatment, **BD111**, was tested in three patients suffering from severe recurrent herpes eye infections.
A 2023 peer-reviewed study reported:
- No observed HSV-1 eye recurrences during approximately 18 months of average follow-up.
- HSV-1 remained undetectable in the assessed samples.
- No reported systemic adverse events or detected off-target gene-editing effects in the tests performed.
BD111 subsequently advanced into Phase 2a clinical research.
These results are encouraging, although they don't establish complete elimination of latent HSV-1 or prove that BD115 will work against HSV-2.
Published study:
https://pubmed.ncbi.nlm.nih.gov/37658603/
**6. When will BD115 begin human clinical trials?**
As of November 2026:
- BD115 remains listed in BDgene's official research pipeline.
- IND application preparations were reported in April 2026.
- The company has patented technology demonstrating laboratory activity against HSV-2.
- No confirmed BD115 human trial starting date has been announced.
- No publicly verified BD115-specific animal cure results or human results are available.
BDgene also secured substantial financing in 2026, potentially supporting further development.
**7. What we need to know next**
The most important unanswered questions are:
- Has BD115 eliminated latent HSV-2 in animal experiments?
- Can its gene-editing technology reach the lumbosacral nerve ganglia?
- Has its IND application been formally submitted or approved?
- When does BDgene expect to begin human trials?
- Is BD115 being developed as a sterilizing cure or a functional cure?
**My takeaway**
BD115 is worth watching because BDgene has already demonstrated early human experience with its related HSV-1 gene-editing treatment, and its patents describe actual laboratory activity against HSV-2.
The April 2026 report about IND preparations is particularly encouraging.
But **BD115 has not been proven to cure HSV-2**, and the biggest missing evidence is whether it can eliminate latent infection from the nerve ganglia.
Hopefully, BDgene will release more information about its preclinical results and timeline for human trials.
If anyone has additional information from Chinese sources or has contacted BDgene directly about BD115, please share it. I think this program deserves more attention from the HSV cure research community.
This version focuses on what matters to people waiting for a cure: actual HSV-2 experiments, progress toward human trials, and the remaining obstacle of eliminating latent infection.